- TYPE I DIABETES -- GET OFF INSULIN
- Nature's platform.
- IT IS...WHAT IT IS...
- Little things that could be the start of something big!
- A Special Interview with Jeffrey Smith By Dr. Mercola
- Fry your brain with your cell phone?
- Aluminum another culprit in vaccine toxicity
- Why You Should Avoid Conventional Chicken
- Functional Neurology --- What Is It?
- How Schools Unwittingly Promote Learning Disabilities and Illnesses…
- Climbing Tiny Mountians... Part 4
- "Climbing Tiny Mountains..." Part 3
- "Climbing Tiny Mountains..." Part 2
- A Call for Social Stories!
- Ginger Spice Induces Hara-Kiri in Leukemia Cells
- The Meaning Of The Dancing Butterfly
- Showing Teeth...
- Michael Pollan On Oprah
- 'Food Matters': A movie that could save your life
- The yogic art of "ocean breathing"
Stop, Listen, Pray, Meditate
8 Dec 2013 | 7:34 pm
I woke up yesterday morning and for some reason I felt an urge to sit on the side of my bed and immediately began to meditate and pray. I usually go into the living room, relax with a cup of my homemade tea or some coffee, and ease into my day with my meditation and prayer practice. But yesterday I felt I had to begin immediately after waking up. I sat and at first I just listened. I focused on my breath and listened to the inner whisper that told me today someone unexpected would need me to be there
Singer Susan Boyle reveals she has Asperger's syndrome: paper
8 Dec 2013 | 11:51 am
(Reuters) - Scottish singer Susan Boyle says she has a form of autism known as Asperger's syndrome, a diagnosis she says came as a relief after years of believing she had brain damage. Boyle, 52, told the Observer newspaper in an interview published Saturday she had sought help from a Scottish specialist a year ago believing her childhood diagnosis of brain damage was incorrect. "I was told I had brain damage.
AbbVie leukemia drug impresses in early-stage trial
8 Dec 2013 | 9:30 am
An experimental AbbVie Inc drug for leukemia controlled or eliminated signs of the disease in more than 80 percent of patients who had failed to benefit from previous treatments, an unprecedented finding that could spur use of the medicine for other cancers, researchers said. The AbbVie drug, ABT-199, works by blocking a protein called BCL-2 that allows cancer cells to overcome a natural mechanism called programmed cell death, in which the body kills off defective or cancerous cells. The favorable data was seen in a phase I, or early-stage, trial involving 67 patients with chronic lymphocytic leukemia who had not been helped by chemotherapy or relapsed from such treatment. "To achieve that magnitude of complete remission is extraordinarily promising and unprecedented in this particular type of leukemia, among patients with otherwise resistant disease," Dr. John Seymour, a researcher with the Peter MacCallum Cancer Centre in Melbourne, Australia, said in a telephone interview.
J&J, Pharmacyclics leukemia drug effective long term: study
8 Dec 2013 | 9:09 am
A closely watched leukemia drug developed by Johnson & Johnson and Pharmacyclics Inc maintained its effectiveness in keeping the disease at bay for most patients, according to long-term follow-up data from a midstage study being presented at a major medical meeting. The oral drug, ibrutinib, last month won U.S. approval to treat a rare and aggressive form of non-Hodgkin lymphoma known as mantle cell lymphoma. It is awaiting a Food and Drug Administration decision on treating chronic lymphocytic leukemia (CLL), a slowly progressing form of blood cancer that primarily affects people aged 65 and older. Some industry analysts had expected the CLL approval to come at the same time as the lymphoma decision.
Teva bets on new therapeutic uses of known molecules
8 Dec 2013 | 9:04 am
By Tova Cohen TEL AVIV (Reuters) - Teva Pharmaceutical Industries, the world's biggest maker of generic drugs, estimates its pipeline of so-called new therapeutic entities (NTEs) could generate revenue of $1 billion to $1.5 billion by 2018. This figure could jump to $3 billion in 2020, Elisabeth Kogan, Teva's senior vice president of generic research and development, told reporters on Sunday. The NTE program, launched a year ago, is a major element in Teva's strategy for growth and the company has 15 such products in its pipeline. One such product, called Adasuve, which it licensed from Alexza Pharmaceuticals, has been approved and is expected to be launched in the United States in about a month, Teva officials said.
China bans shark fin dinners, suites for officials in latest crackdown
8 Dec 2013 | 8:55 am
Chinese authorities have banned shark fin and bird's nest soup from official receptions and told lower level officials they cannot stay in suites on business trips in the latest step in a crackdown on extravagance and waste. The official Xinhua news agency said on Sunday that cigarettes and expensive alcoholic drinks were also banned from official receptions, citing a document issued by the Communist Party's Central Committee and the State Council. "Shark fins, bird nests and products of rare wild animals are popular materials in luxury dinners in China," Xinhua cited the document as saying. "Officials on business tours should arrange their own meals according to relevant expenditure standards." Chinese President Xi Jinping has sought to address growing public anger at the illegal or unethical behavior of party officials, especially those with flamboyant lifestyles, often seen as a sign they are corrupt.
The Top 10 Workout Songs for December 2013
8 Dec 2013 | 7:36 am
8 Ridiculously Cheap Superfoods Less Than $1 Per Serving
8 Dec 2013 | 7:15 am
It's not just an excuse: Nutritious eats really are more expensive than food that won't do a body good. According to a new study, healthful food is $1.50 more expensive per day, or about $550 per year. But that certainly doesn't mean you can give up on fruits and veggies, nor does it mean that lean meats and whole grains have to break the bank. Here are eight of our favorite superfoods -- all of which cost less than a buck per serving. Now that's delicious! Cost per serving calculated by The Huffington Post using data from the Bureau of
The BRFWA Process
8 Dec 2013 | 7:15 am
Often in the yoga world, you'll hear directions like, "Let it go," "Relax," "Breathe into it." These all sound lovely, but when I'm in a wound-up state, they strike me as abstract, unattainable, and a tad annoying. Let what go, where? Relax? Thanks, I'll get right on that. And breathe into what?
Engagement In An Activity Boosts Life Satisfaction, Ski Study Shows
8 Dec 2013 | 7:13 am
- No End in Sight to the Bull Market in Stocks
- The Biggest Stock Gains in 2014
- More Help From the Fed
- Stock Market Rally Watch
- A Danger Sign That Stock Investors Will Ignore
- US Stocks Near a Record High and Want to Rise Even Further
- The Three Reasons Oil Will Soar Again - After It Bottoms
- Is the Stock Market Rally About to End?
- Gold and commodities going down or up near term and in future?
- College Graduation Celebration Goes Bad!
- What food is it that causes the most grief and suffering for years after eating it?
- How to Make Rising Interest Rates Work for You - The Future of Gold
- Most Profitable Time For Gold and Gold Miner Stocks - Is It Time Yet?
- What About Inflation? Is it Dead?
- Gold and Silver 15% Surge in GDXJ Indicates Potential Major Bottom